Lipocine hosts KOL event on postpartum depression

Lipocine Inc. filed a report describing a virtual key opinion leader event held on June 12, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. filed a report describing a virtual key opinion leader event held on June 12, 2026. The event focused on unmet medical needs in postpartum depression and reviewed the clinical profile of the company’s investigational product candidate LPCN 1154.

The related slide presentation was furnished as Exhibit 99.1 and is incorporated by reference. Lipocine notes that a link to the presentation is available on its corporate website, giving investors and clinicians access to the detailed discussion from the event.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

postpartum depression, key opinion leader, clinical profile, emerging growth company

4 terms

postpartum depression medical

"event highlighting the unmet needs in postpartum depression and the clinical profile"

A mood disorder that can arise after childbirth, characterized by persistent sadness, anxiety, exhaustion and difficulty caring for oneself or a baby; it can range from moderate to severe and often requires medical or therapeutic treatment. Investors care because its prevalence affects demand for medical treatments, mental-health services and parental workplace policies, and can influence healthcare spending, drug development programs, and productivity in sectors that depend on caregiver labor — much like a widespread recurring expense that changes consumer and employer behavior.

key opinion leader financial

"the Company hosted a virtual key opinion leader (“KOL”) event highlighting"

A key opinion leader is an individual whose insights, expertise, or influence significantly shape the opinions and decisions of others within a particular field or community. For investors, they are like trusted guides whose views can impact market trends or perceptions, making their perspectives important to watch. Their influence often stems from experience, reputation, or widespread respect among peers.

clinical profile medical

"highlighting the unmet needs in postpartum depression and the clinical profile of LPCN 1154"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine Inc. (LPCN) disclose in its latest 8-K filing?

Lipocine disclosed that it hosted a virtual key opinion leader event on June 12, 2026, focused on unmet needs in postpartum depression and the clinical profile of LPCN 1154. The associated presentation was furnished as Exhibit 99.1 and is available via the corporate website.

What was the focus of Lipocine (LPCN) June 12, 2026 KOL event?

The virtual KOL event highlighted unmet needs in postpartum depression and presented the clinical profile of LPCN 1154. Lipocine used the session to share scientific and clinical information with experts, supported by a detailed slide presentation filed as Exhibit 99.1.

Where can investors view Lipocine’s LPCN 1154 KOL presentation?

Investors can access the LPCN 1154 KOL presentation through a link on Lipocine’s corporate website. The same presentation is also furnished as Exhibit 99.1 in the report, providing consistent information for all interested stakeholders.

What is Exhibit 99.1 in Lipocine’s (LPCN) recent report?

Exhibit 99.1 is the slide presentation from Lipocine’s virtual key opinion leader event on postpartum depression and LPCN 1154. It contains the materials shown during the event and is formally incorporated by reference in the company’s report.

Does Lipocine’s 8-K mention LPCN 1154 by name?

Yes, the report specifically refers to LPCN 1154, describing the KOL event as highlighting its clinical profile. This positions LPCN 1154 as the central product candidate discussed during the postpartum depression-focused presentation filed as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/12/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

June 12, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

On June 12, 2026, the Company hosted a virtual key opinion leader (“KOL”) event highlighting the unmet needs in postpartum depression and the clinical profile of LPCN 1154. The presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein. A link to the presentation is available on the corporate website at www.lipocine.com.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description

99.1		Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 Presentation

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.